Table 1.
Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Against Type-Specific HPV Positivity
| HPV Typea | VE (95% CI)b | No., Total (No. Vaccinated/No. Nonvaccinated)c | Reference Genomed | Hamming Distancee |
|---|---|---|---|---|
| High-risk | ||||
| 16 | 0.92 (.86–.96) | 100 (13/87) | gi|333031|lcl|HPV16REF.1 | 37 |
| 18 | 0.89 (.78–.94) | 63 (11/52) | gi|60975|lcl|HPV18REF.1 | 41 |
| 31 | 0.66 (.51–.77) | 129 (50/79) | gi|333048|lcl|HPV31REF.1 | 102 |
| 33 | 0.41 (.05–.63) | 73 (37/36) | gi|333049|lcl|HPV33REF.1 | 111 |
| 35 | 0.40 (−.03 to .65) | 55 (28/27) | gi|396997|lcl|HPV35REF.1 | 105 |
| 39 | 0.15 (−.19 to .39) | 165 (98/67) | gi|333245|lcl|HPV39REF.1 | 128 |
| 45 | 0.81 (.55–.92) | 28 (7/21) | gi|397022|lcl|HPV45REF.1 | 91 |
| 51 | −0.24 (−.54 to .01) | 522 (345/177) | gi|333087|lcl|HPV51REF.1 | 180 |
| 52 | 0.36 (.19–.50) | 342 (185/157) | gi|397038|lcl|HPV52REF.1 | 117 |
| 56 | −0.17 (−.59 to .14) | 220 (145/75) | gi|397053|lcl|HPV56REF.1 | 173 |
| 58 | 0.30 (−.06 to .54) | 95 (52/43) | gi|222386|lcl|HPV58REF.1 | 113 |
| 59 | −0.95 (−2.17 to −.20) | 96 (73/23) | gi|557236|lcl|HPV59REF.1 | 125 |
| Probable high-risk | ||||
| 53 | 0.26 (.05–.43) | 332 (189/143) | gi|9627377|lcl|HPV53REF.1 | 173 |
| 66 | 0.02 (−.26 to .24) | 340 (212/128) | gi|1020290|lcl|HPV66REF.1 | 174 |
| 68/73/97 | −0.08 (−.63 to .28) | 110 (71/39) | gi|71726685|lcl|HPV68REF.1 | 139 |
| gi|1491692|lcl|HPV73REF.1 | 150 | |||
| gi|71726694|lcl|HPV97REF.1 | 89 | |||
| Low-risk | ||||
| 6 | −0.15 (−.52 to .14) | 263 (172/91) | gi|60955|lcl|HPV6REF.1 | 161 |
| 11 | −0.07 (−1.00 to .42) | 45 (29/16) | gi|333026|lcl|HPV11REF.1 | 162 |
| 34 | 0.00 (−1.57 to .61) | 19 (12/7) | gi|9627334|lcl|HPV34REF.1 | 154 |
| 40 | 0.08 (−.68 to .50) | 46 (28/18) | gi|397014|lcl|HPV40REF.1 | 163 |
| 42 | −1.27 (−3.34 to −.19) | 57 (45/12) | gi|333211|lcl|HPV42REF.1 | 160 |
| 43 | −0.78 (−2.13 to −.01) | 67 (50/17) | gi|40804474|lcl|HPV43REF.1 | 176 |
| 44 | −0.32 (−1.30 to .24) | 61 (42/19) | gi|1020242|lcl|HPV44REF.1 | 162 |
| 54 | −0.34 (−.95 to .08) | 141 (97/44) | gi|9628437|lcl|HPV54REF.1 | 143 |
| 70 | 0.02 (−1.03 to .52) | 32 (20/12) | gi|1173493|lcl|HPV70REF.1 | 126 |
| 74 | 0.26 (−.19 to .54) | 75 (42/33) | gi|27462483|lcl|HPV74REF.1 | 168 |
Abbreviations: CI, confidence interval; HPV, human papillomavirus.
aHPV genotypes in the SPF10-LiPA25 assay, with 68 being indistinguishable from 73 and 97.
bVE (with 95% CI) was calculated as 1 minus the adjusted odds ratio from a logistic mixed model described in [6].
cNo. of positive test results (among 1305 vaccinated + 799 nonvaccinated women) used in VE estimation.
dWhole-genome reference DNA sequences obtained from the papillomavirus genome database (https://pave.niaid.nih.gov/).
eMinimum number of different amino acids between aligned L1 sequences of reference types and virus-like particles in bivalent vaccine.